• D-SCOUT

    A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of Deferoxamine Intradermal Delivery Patch (DIDP) in Chronic Sickle Cell Leg

    The primary purpose of this study is to evaluate the safety and tolerability of Deferoxamin Intradermal Delivery Patch applied to non-healing cutaneous leg ulcers in patients with sickle cell disease. Participants for this study will include both males and females over the age of 18 years of age.

    Contact Information

    Julie Kanter, MD (Contact PI)

    Emily Warner (Program Director)

    Ronson Washington (Site Coordinator)

  • RAISE-UP

    A Phase I/II Randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis

    The primary objective of this study is to assess the safety, tolerability and immunogenicity of SHP655 in subjects with Sickle Cell Disease at baseline health and during acute VOC. SHP655 is the investigational drug for this clinical trial. SHP655 is a recombinant ADAMTS-13 that hopes to reduce the symptoms of Sickle Cell Disease by increasing the amount of ADAMTS-13 in patients’ blood. Participants for this study will include both males and females ages 18 to 65. 

    Contact Information

    Julie Kanter, MD (Contact PI)

    Emily Warner (Program Director)

    Ronson Washington (Site Coordinator)

  • SPARTAN

    A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (crizanlizumab), in Sickle Cell Disease Patients with Priapism

    The primary purpose of this study is to evaluate the effect of crizanlizumab on priapic episodes in sickle cell patients with a history of priapism. Crizanlizumab (SEG101) is the investigational drug for this clinical trial. Crizanlizumab is an antibody that was designed to attach to proteins on the cells in the blood and blood vessels that cause VOC and prevent these cells from sticking together.  Participants for this study will include males ages 18 years of age and older.

    Contact Information

    Julie Kanter, MD (Contact PI)

    Emily Warner (Program Director)

    Ronson Washington (Site Coordinator)

  • STEADFAST

    A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

    The primary purpose of this study is to evaluate the effect of crizanlizumab on kidney function in people with long-term kidney disease caused by sickle cell disease. Crizanlizumab (SEG101) is the investigational drug for this clinical trial. Crizanlizumab is an antibody that prevents the attachment of certain blood cells to the inside of the blood vessels that cause painful crisis (or VOC) in order to prevent these cells from sticking together.  Participants for this study will include both males and females ages 18 years of age and older. 

    Contact Information

    Julie Kanter, MD (Contact PI)

    Emily Warner (Program Director)

    Ronson Washington (Site Coordinator)

  • IMR-SCD-301

    A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

    The primary purpose of this study is to evaluate the fetal hemoglobin response to IMR-687 versus placebo and to evaluate the safety of IMR-687 versus placebo.  IMR-687 is the investigational drug for this clinical trial. The study drug is designed to increase the levels of a particular form of hemoglobin called fetal hemoglobin (also known as Hemoglobin F or HbF). Participants for this study will include both males and females ages 18 to 65 years older.

    Contact Information

    Julie Kanter, MD (Contact PI)

    Emily Warner (Program Director)

    Ronson Washington (Site Coordinator)